Literature DB >> 6381789

Pathogenesis and treatment of aplastic anemia.

B M Camitta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6381789

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN： 0485-1439


× No keyword cloud information.
  8 in total

1.  Outcome of Cyclosporine Monotherapy in Patients of Aplastic Anemia: Experience of a Tertiary Care Hospital in Eastern India.

Authors:  Prakas Kumar Mandal; Suvraneel Baul; Tuphan Kanti Dolai; Rajib De; Prantar Chakrabarti
Journal:  Indian J Hematol Blood Transfus       Date:  2016-07-19       Impact factor: 0.900

Review 2.  Diagnosis and Treatment of Aplastic Anemia.

Authors:  Scott A Peslak; Timothy Olson; Daria V Babushok
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

3.  The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis.

Authors:  Yash B Shah; Salvatore F Priore; Yimei Li; Chi N Tang; Peter Nicholas; Peter Kurre; Timothy S Olson; Daria V Babushok
Journal:  Blood Adv       Date:  2021-08-24

4.  Outcomes of haploidentical bone marrow transplantation in patients with severe aplastic anemia-II that progressed from non-severe acquired aplastic anemia.

Authors:  Hongchen Liu; Xiaoli Zheng; Chengtao Zhang; Jiajun Xie; Beibei Gao; Jing Shao; Yan Yang; Hengxiang Wang; Jinsong Yan
Journal:  Front Med       Date:  2021-06-25       Impact factor: 4.592

5.  Should we still use Camitta's criteria for severe aplastic anemia?

Authors:  Hyun Hwa Yoon; Seok Jae Huh; Ji Hyun Lee; Suee Lee; Sung-Hyun Kim; Hyuk Chan Kwon; Hyo-Jin Kim
Journal:  Korean J Hematol       Date:  2012-06-26

6.  Differentiation of Yin, Yang and Stasis Syndromes in Severe Aplastic Anemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation and Their Correlation with Iron Metabolism, cAMP/cGMP, 17-OH-CS and Thyroxine.

Authors:  Huijin Hu; Tao Chen; Wenbin Liu; Yiping Shen; Qiushuang Li; Yuhong Zhou; Baodong Ye; Dijiong Wu
Journal:  J Blood Med       Date:  2021-11-13

7.  A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy.

Authors:  Guangxin Peng; Guangsheng He; Hong Chang; Sujun Gao; Xinjian Liu; Tong Chen; Pei Li; Bing Han; Miao Miao; Zheng Ge; Xiaoyan Ge; Fei Li; Yingmei Li; Shunqing Wang; Yi Wang; Yaqi Shen; Tao Zhang; Jianjun Zou; Fengkui Zhang
Journal:  Ther Adv Hematol       Date:  2022-03-30

8.  Apolipoprotein-A is a potential prognostic biomarker for severe aplastic anemia patients treated with ATG-based immunosuppressive therapy: a single-center retrospective study.

Authors:  Qi Liu; Huijie Dong; Yuzhu Li; Yingying Shen; Yilei Hong; Ying Chen; Shan Liu; Xiaolian Wu; Wenbin Liu; Huijin Hu; Yuechao Zhao; Shenyun Lin; Yiping Shen; Yuhong Zhou; Baodong Ye; Dijiong Wu
Journal:  Lipids Health Dis       Date:  2022-10-04       Impact factor: 4.315
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.